Just How Large is the Psychedelics Market?
December 16th, 2020
App, Exclusive, Psychedelics, Top Story
The psychedelics industry may appear to have suddenly emerged as one of the hottest corners of the stock market, but researchers have been working for decades to show the efficacy of these treatments and regulators are just starting to appreciate the possibilities.
Investors could see strong growth in the industry as companies commercialize breakthrough therapeutics while patients could finally have access to life-changing treatments for a range of mental health conditions that have no effective treatment options today.
Let’s take a look at the nascent psychedelics industry in terms of both its revenue potential and the valuations that investors are assigning to companies in the space.
Psychedelics by Revenue
The market for psychedelic drugs is projected to grow from just over $2 billion last year to about $6.9 billion by 2027, according to Data Bridge Market Research, which represents a blistering 16.3% compound annual growth rate over the forecast period.
The report authors note that psychedelic drugs are becoming increasingly accepted in the treatment of major depressive disorder, treatment-resistant depression, panic disorder, post-traumatic stress disorder, opiate addiction, eating disorders, and fibromyalgia, among other things.
The global behavioral health market, where psychedelics have shown tremendous potential, could hit $240 billion by 2026, according to Acumen Research and Consulting. Given the ineffectiveness of many existing treatments, psychedelics have blue sky potential in the space.
In addition to the growing body of research, governments have taken an increasingly permissive stance on the drugs. Health Canada recently granted exemptions to a number of healthcare professionals who wanted to possess and consume psilocybin mushrooms.
Several U.S. states have also moved to decriminalize psychedelic drugs, which could enable practitioners to treat patients. Given the size of the largely decriminalized cannabis industry’s sales, these moves could create significant revenue potential even without full legalization.
Psychedelics by Valuation
The growing body of research supporting psychedelics and more widespread acceptance has led to an explosion of investment in the sector. In addition to more than 25 public companies in the space, there are hundreds of privately held companies drawing investment dollars.
Peter Thiel, a famous investor in Facebook and PayPal, became the industry’s most high-profile investor in the space. Meanwhile, Compass Pathways plc (NASDAQ: CMPS) has nearly doubled since its debut on the NASDAQ with a market capitalization of nearly $2 billion.
Despite the impact of COVID-19, psychedelic companies have had little trouble raising substantial amounts of capital to finance their operations. Private companies that have gone public have also seen strong performance in the stock markets.
Tryp Therapeutics Inc., a pharmaceutical company focused on developing synthetic psilocybin for neuropsychiatric disorders, is one of the latest companies to file its final prospectus with plans to go public on the Canadian Securities Exchange (TRYP:CSE) on or about December 18th, 2020.
The company’s Psilocyin-for-Neuropsychiatric disorders, or PFN™ program is focused on developing orally-delivered drug therapies for neuropsychiatric disorders that have ineffective first line treatments in disease categories with high unmet medical needs.
The company’s two development programs include TRP-8802 targeting fibromyalgia, a range of eating disorders (including Prader WIllie Syndrome) and TRP-1001 targeting soft tissue sarcomas. TRP-8802 is the lead indication under its PFN™ program while TRP-1001 could qualify for Orphan Drug status.
Many investors are looking to the psychedelics industry to replicate the success of the cannabis industry—another instance of a once-illegal drug becoming legal for sale. While recreational cannabis has become a commodity, psychedelics could revolutionize medicine.
Investors looking to participate in the industry’s growth can choose from a growing number of public companies in the space, which are primarily traded in Canada on the CSE, where regulations are more permissive and investor appetite is strong.
To learn more about Tryp Therapeutics, visit the company’s website or download their investor presentation.
The above article is sponsored content. CannabisFN.com and CFN Media, have been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: https://cannabisfn.com/legal-disclaimer/
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
Follow Us on Social Media
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.